Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Expected to Announce Earnings of $0.38 Per Share

Analysts forecast that Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will post earnings of $0.38 per share for the current quarter, Zacks reports. Four analysts have made estimates for Amphastar Pharmaceuticals’ earnings. The highest EPS estimate is $0.51 and the lowest is $0.33. Amphastar Pharmaceuticals reported earnings per share of $0.16 during the same quarter last year, which suggests a positive year over year growth rate of 137.5%. The business is scheduled to report its next earnings report on Monday, March 21st.

On average, analysts expect that Amphastar Pharmaceuticals will report full year earnings of $1.33 per share for the current year, with EPS estimates ranging from $1.29 to $1.44. For the next fiscal year, analysts anticipate that the business will report earnings of $1.46 per share, with EPS estimates ranging from $1.36 to $1.66. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Monday, November 8th. The company reported $0.46 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.22. Amphastar Pharmaceuticals had a net margin of 8.74% and a return on equity of 12.28%. During the same quarter in the previous year, the company posted $0.09 EPS.

Several equities analysts have issued reports on AMPH shares. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $24.00 target price on the stock in a research note on Monday, November 15th. TheStreet upgraded shares of Amphastar Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Wednesday, October 20th.

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 11th. The shares were sold at an average price of $21.33, for a total transaction of $213,300.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 22nd. The stock was sold at an average price of $21.22, for a total transaction of $106,100.00. The disclosure for this sale can be found here. Insiders sold a total of 22,813 shares of company stock worth $488,708 in the last quarter. Company insiders own 28.40% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its position in Amphastar Pharmaceuticals by 9.5% in the second quarter. Renaissance Technologies LLC now owns 247,100 shares of the company’s stock worth $4,982,000 after buying an additional 21,500 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Amphastar Pharmaceuticals by 0.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,695,893 shares of the company’s stock valued at $34,189,000 after acquiring an additional 6,804 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 3.3% in the first quarter. Ameriprise Financial Inc. now owns 194,086 shares of the company’s stock valued at $3,555,000 after acquiring an additional 6,202 shares in the last quarter. Factorial Partners LLC purchased a new position in Amphastar Pharmaceuticals in the second quarter valued at about $403,000. Finally, ProShare Advisors LLC grew its stake in Amphastar Pharmaceuticals by 10.2% in the second quarter. ProShare Advisors LLC now owns 19,158 shares of the company’s stock valued at $386,000 after purchasing an additional 1,768 shares during the last quarter. Institutional investors own 56.49% of the company’s stock.

AMPH traded down $0.26 during midday trading on Thursday, hitting $20.92. 121,263 shares of the company traded hands, compared to its average volume of 192,150. The company has a quick ratio of 2.08, a current ratio of 3.10 and a debt-to-equity ratio of 0.18. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of 29.06 and a beta of 0.70. The firm has a 50-day moving average of $19.42. Amphastar Pharmaceuticals has a 52 week low of $16.91 and a 52 week high of $21.70.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs.

Featured Story: What is the price-sales ratio?

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.